Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

WuXi and PRA Form Joint Venture

Published: Tuesday, January 01, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
The agreement will offer a broad platform of Phase I-IV clinical trial services in China, Hong Kong and Macau.

The joint venture will provide services including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting, and medical monitoring.

The clinical operations of WuXi and PRA in China will combine to operate as an independent CRO and will be jointly owned by their respective parent companies. WuXi will contribute clinical and regulatory experience to the joint venture from its China-based clinical organization. That organization covers all regions of the country and has employees working in 16 Chinese cities, with offices in Shanghai, Beijing and Guangzhou. WuXi will also supply laboratory services to the joint venture through a preferred provider arrangement. PRA offers the venture a wealth of global resources and clinical research expertise, reflected in more than 3,100 studies conducted over the last five years and contributions to 40 approved drugs in several therapeutic areas. PRA will also support the venture with itsChina-based staff and global technology capabilities, encompassing data capture, trial management and other IT systems. The companies will market the joint venture's services to their respective customers.

"We are delighted to partner with PRA to build the leading clinical-trial services operation in China," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "China's pharmaceutical market today is the third largest in the world and growing very rapidly. Biopharmaceutical companies increasingly need sophisticated clinical-trial management services to gather the highest-quality data in Chinese patients to complete Chinese and international regulatory filings as quickly and successfully as possible. We aim to become the clinical trial service provider of choice in China with the highest quality standards and operational excellence."

"PRA's global experience and technical expertise and WuXi's operational experience and knowledge in China are a perfect fit," said Colin Shannon, President and CEO, PRA. "Our companies also share a culture dedicated to delivering excellent customer service, valuing employees and meeting the highest standards of quality. Clinical trials continue to expand in China, and this joint venture is another step we are taking to meet the needs of our clients by establishing a strong presence there. We look forward to working with WuXi to serve global life science companies conducting studies in China."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WuXi PharmaTech and Lilly Announce Strategic Collaboration
Collaboration to develop, manufacture and commercialize a novel small molecule in China.
Saturday, November 14, 2015
WuXi, Lilly Announce Strategic Collaboration
WuXi PharmaTech and Eli Lilly have announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
Thursday, November 12, 2015
WuXi PharmaTech Receives First Approval from Japanese Regulatory Authorities
STA subsidiary receives approval for the manufacture of the GMP intermediate of a branded commercial drug.
Thursday, September 03, 2015
WuXi PharmaTech and TruTag Complete Successful Testing of Authentication Solution
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Thursday, August 20, 2015
WuXi and TruTag Complete Successful Testing of Edible On-Dose Authentication Solution for Pharmaceuticals
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Wednesday, August 12, 2015
WuXi PharmaTech to Build New Cell Therapy Manufacturing Facility
Facility is designed for CAR T cells and other cancer immunotherapies.
Friday, March 20, 2015
WuXi Acquires NextCODE Health
NextCODE and WuXi's Genome Center will offer comprehensive clinical, research, and diagnostic testing products and services worldwide.
Monday, January 12, 2015
WuXi Opening Offices in Boston and San Francisco
New offices will give access to innovative companies in the world's two leading biotech hubs.
Friday, December 19, 2014
WuXi PharmaTech Laboratory Testing Division Expands in U.S.
XenoBiotic acquisition expands LTD’s presence in North America.
Wednesday, October 08, 2014
WuXi Facility Passes FDA API Manufacture Inspection
Company's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) passed an FDA inspection in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug.
Wednesday, August 20, 2014
WuXi PharmaTech Begins Operation of New HPAPI Laboratory
Adds HPAPI processing capabilities at Shanghai lab.
Thursday, May 29, 2014
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
Company announces that construction has been completed on a new biologics biosafety testing facility in Suzhou.
Tuesday, May 13, 2014
WuXi Breaks Ground on New Cell Therapy Manufacturing Facility
The facility in Philadelphia is expected to become operational in the second quarter of 2015.
Thursday, May 01, 2014
WuXi PharmaTech Announces Management Appointments
Dr. Steve Yang joins Company as EVP and chief operating officer and Edward Hu named chief investment officer and remains chief financial officer.
Thursday, April 17, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos